N. Mach , E. Fernandez , R. Vernet , M. Urwyler , O. von Rohr , E. Charrier , M-C. Belkouch , V. Saingier , F. Courtout , C. de Vito , V. Ancrenaz , N. Dulguerov , W. Karenovics , J. Grogg , J. Renaux , T. Brezina , T. Rordorf , M. Joerger , O.A. Michielin , J. Villard
{"title":"在开放标记I期和IIa期临床试验中,所有复发/转移性头颈部鳞状细胞癌(R/M HNSCC)患者接受MVX-ONCO-1治疗的长期生存数据","authors":"N. Mach , E. Fernandez , R. Vernet , M. Urwyler , O. von Rohr , E. Charrier , M-C. Belkouch , V. Saingier , F. Courtout , C. de Vito , V. Ancrenaz , N. Dulguerov , W. Karenovics , J. Grogg , J. Renaux , T. Brezina , T. Rordorf , M. Joerger , O.A. Michielin , J. Villard","doi":"10.1016/j.iotech.2024.100870","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100870"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"59P Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials\",\"authors\":\"N. Mach , E. Fernandez , R. Vernet , M. Urwyler , O. von Rohr , E. Charrier , M-C. Belkouch , V. Saingier , F. Courtout , C. de Vito , V. Ancrenaz , N. Dulguerov , W. Karenovics , J. Grogg , J. Renaux , T. Brezina , T. Rordorf , M. Joerger , O.A. Michielin , J. Villard\",\"doi\":\"10.1016/j.iotech.2024.100870\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73352,\"journal\":{\"name\":\"Immuno-oncology technology\",\"volume\":\"24 \",\"pages\":\"Article 100870\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-oncology technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590018824001679\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
59P Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials